The B cell in systemic lupus erythaematosus: A rational target for more effective therapy

Annals of the Rheumatic Diseases

Volumn 67, Issue 10, 2008, Pages 1374-1381

  Driver, C B ^a   Ishimori, M ^a   Weisman, M H ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; AUTOANTIBODY; AZATHIOPRINE; B CELL ACTIVATING FACTOR; B7 ANTIGEN; BELIMUMAB; CD20 ANTIGEN; CD22 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOATTRACTANT; CORTICOSTEROID; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIBODY PRODUCTION; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BIOASSAY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SPECIFICITY; CLINICAL TRIAL; COMORBIDITY; COMPLEMENT SYSTEM; CYTOPATHOLOGY; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; GRANULOCYTE; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MACROPHAGE; MUTATION; NATURAL KILLER CELL; NON HODGKIN'S LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION;

ANIMALS; ANTIGENS, CD; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MICE;

EID: 53149143906     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.076745     Document Type: Review

References (122)

1. Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005;23(Suppl 39):S120-32.
2. Gill JM, Quisel AM, Rocca PV, Walters DT. Diagnosis of systemic lupus erythematosus. Am Fam Physician 2003;68:2179-86.
3. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3:423-53.
4. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004;13:673-8.
5. American College of Rheumatology Ad Hoc Committee on Systemic lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999;42:1785-96.
6. Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004;33:336-51.
7. Casado E, Gratacos J, Tolosa C, Martinez JM, Ojanguren I, Ariza A, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006;65:385-90.
8. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 2000;39:389- 92.
9. Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake 0, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005;64:111-3.
10. Goeb V, Berthelot JM, Joly P, Mejjad 0, de Quatrebarbes J, Reynaud-Hautin C, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2005;44:823-4.
11. Park NIC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004;13:569-74.
12. Alarcon GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 2004;43:202-5.
13. Anolik J, Sanz I. B Cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:505-12.
14. Renaudineau Y, Pers JO, Bendaoud B, Jamin C, Youinou P. Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 2004;3:516-23.
15. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-90.
16. Eisenberg R. SLE - Rituximab in lupus. Arthritis Res Ther 2003;5:157-9.
17. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006;5:18-24.
18. Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005;52:371-7.
19. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005;14:210-4.
20. Sfikakis PP, Boletis JN. Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7.
21. Looney RJ, Anolik J, Sanz I. B Cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004;16:180-5.
22. Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004;13:381-90.
23. Looney RJ, Anolik J, Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 2005;8:193-205.
24. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
25. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:1129-37.
26. Jacobi AM, Diamond B. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 2005;202:341-4.
27. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-11.
28. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:705-10.
29. Youinou P, Jamin C, Pers JO, Berthou C, Saraux A, Renaudineau Y. B lymphocytes are required for development and treatment of autoimmune diseases. Ann NYAcad Sci 2005;1050:19-33.
30. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
31. Chan OT, Madaio MP, Shlomchik MJ. B Cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol 1999;163:3592-6.
32. Reininger L, Winkler TH, Kalberer CP, Jourdan M, Melchers F, Rolink AG. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB x NZW)F1 mice. J Exp Med 1996;184:853- 61.
33. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-8.
34. Sato T, Ishikawa S, Akadegawa K, Ito T, Yurino H, Kitabatake M, et al. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur J Immunol 2004;34:3346-58.
35. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580- 90.
36. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, ef al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
37. Bohm I. Increased peripheral Blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother 2004;58:338-43.
38. Ryan EP, Pollock SJ, Murant Tl, Bernstein SH, Felgar RE, Phipps RP. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol 2005;174:2619- 26.
39. Bellosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D, et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998;92:1406-14.
40. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001;10:140-7.
41. Stohl W. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun 2005;8:289-304.
42. Amano H, Morimoto S, Kaneko H, Tokano Y, Takasaki Y, Hashimoto H. Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. Lupus 2000;9:26-32.
43. McConkey DJ, Aguilar-Santelises M, Hartzell P, Eriksson I, Mellstedt H, Orrenius S, et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol 1991;146:1072-6.
44. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61:635-42.
45. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000;95:3460-6.
46. Lombard-Platlet S, Bertolino P, Deng H, Gerlier D, Rabourdin-Combe C. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology 1993;80:566-73.
47. Lagneaux L, Delforge A, Carlier S, Massy M, Bernier M, Bron D. Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br J Haematol 2001;112:344-52.
48. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006;54:3068-70.
49. Tareyeva IE, Shilov EM, Gordovskaya NB. The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis. Clin Nephrol 1980;14:233-7.
50. Bohm J. Decrease of B-cells and autoantibodies after low-dose methotrexate, Biomed Pharmacother 2003;57:278-81.
51. Lacki JK, Mackiewicz SH, Leszczynski P, Muller W. The effect of intravenous cyclophosphamide pulse on peripheral Blood lymphocytes in lupus erythematosus patients. Rheumatol Int 1997;17:55-60.
52. Takeno M, Suzuki N, Nagafuchi H, Mizushima Y, Sakane T. Selective suppression of resting B cell function in patients with systemic lupus erythematosus treated with cyclophosphamide. Clin Exp Rheumatol 1993;11:263-70.
53. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):s2-8.
54. Lewis MJ, D'Cruz D. Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus. Lupus 2005;14(Suppl 1):s17-26.
55. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997;15:481-504.
56. Domer T, Kaufmann J, Wegener WA. Teoh N. Goldenberg DM, Burmester GR, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
57. Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T, et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum 2003;48:1612-21
58. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982S-90S.
59. Cragg MS, Walshe CA, Ivanov A0, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74.
60. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993;14:196-204.
61. Sandilands GP, Perry M, Wootton M, Hair J, More IA. B-cell antigens within normal and activated human T cells. Immunology 1999;96:424-33.
62. Tedder TF, Boyd AW, Freedman AS. Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985;135:973-9.
63. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 2005;44:561-2.
64. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anticancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-8.
65. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
66. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 IIDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-86.
67. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
68. Keystone E. B Cell targeted therapies. Arthritis Res Ther 2005;7(Suppl 3):S13-8
69. Tsokos GC. B Cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 2004;350:2546-8.
70. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30(Suppl 2):3-8.
71. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E. et al. Complement activation determines the therapeutic activity of rituximab in vivo. J lmmunol 2003;171:1581-7.
72. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, et al. Downregulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176-82.
73. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of prolrferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
74. Leandro MJ, Edwards JCW, Cambridge G, Ehrenstein MR. B-cell repopulation occurs mainly from naive B cells in patients with rheumatoid arthritis and systemic lupus erythematosus treated with rituximab. Arthritis Rheum 2003;48(Suppl S):S464.
75. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral Blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
76. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26.
77. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology {Oxford) 2005;44:1542-5.
78. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, Sundelin B, Osterborg A, Jacobson SH, ef al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004;33:423-7.
79. Looney RJ, Anolik JH. Campbell D, felgar RE, Young F, Arend LJ, et al. B Cell depletion as a novel treatment for systemic lupus erythematosus: a phase l/ll doseescalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
80. Albert D, Khan S, Stansberry J, Kolasinski S, Tsai D, Kamoun M, et al. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus. Arthritis Rheum 2004;50(Suppl S):S446-7.
81. Ryan JP, Singer NG. Scalzi LV. Treatment of resistant SLE with rituximab administered without cyclophosphamide. Arthritis Rheum 2004;50(Suppl S):S413-4
82. Neuwelt CM, Young RG, McGhee RA, Freeman J. Role of rituximab in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus as monotherapy or in combination therapy. Ann Rheum Dis 2005;64(Suppl 3):57.
83. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR. Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
84. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
85. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-475.
86. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, Jonsdottir T, Sundelin B, Jacobsson S, et al. Rituximab plus cyclophosphamide in severe SLE: results in 15 patients who failed conventional immunosuppressive therapy. Arthritis Rheum 2005;52(Suppl S):S741.
87. Ng KP, Leandro MJ, Edwards JCW, Ehrenstein M, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Arthritis Rheum 2005;52(Suppl S):S197.
88. US National Institutes of Health. ClinicalTrials.gov website. http://www.clinicaltrials.gov/ct (accessed 18 January 2007).
89. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
90. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R83.
91. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5.
92. American College of Rheumatology. Hotline: Rituximab and Progressive Multifocal Leukoencephalopathy. http://rheumatology.org/ publications/hotline/0107leuko.asp (accessed 12 August 2008).
93. US Food and Drug Administration. Medwatch. http://www.fda.gov/ medwatch/safety/2006/safety06.htm#Rituxan (accessed 16 May 2007).
94. Zhang W, Fischer R, He LS, Pisitkun P, Gaffney P, Behrens T, et al. An SLE- associated mutation in CD40 alters human B cell function. Arthritis Rheum 2005;52(Suppl S):S287-8.
95. Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 2004;13:377-80.
96. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
97. Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, et al. The effect of anti-CD40 ligand antiboy on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46:1554-62.
98. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004;13:391-7.
99. Kuwana M, Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, et al. Autoantibody to CD40 ligand is associated with thrombocytopenia, but not with thromboembolism. Arthritis Rheum 2004;50(Suppl S):S600.
100. Dall'ra M, Davis J. CTLA41g: a novel inhibitor of costimulation. Lupus 2004;13:372-6.
101. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA41g takes on lupus. Lupus 2005;14:197-203.
102. Daikh Dl, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA41g and cyclophosphamide. J Immunol 2001;166:2913-6.
103. Cunnane G, Chan OT, Cassafer G, Brindis S, Kaufman E, Yen TS, et al. Prevention of renal damage in murine lupus nephritis by CTLA-41g and cyclophosphamide. Arthritis Rheum 2004;50:1539-48.
104. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-lg in murine systemic lupus erythematosus. J Immunol 2004;173:3524-34.
105. Akkerman A, Huang W, Wang X, Ramanujam M, Schiffer L, Madaio M, et al. CTLA41g prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004;37:445-51.
106. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, et al. B Cellactivating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-17.
107. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cellactivating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005;36:1113-9.
108. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
109. Kayagaki N. Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kB2. Immunity 2002;17:515-24.
110. Furie R, Stohl W, Ginzler E, Becker M, Mishra N, Chatham W, et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double doseescalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003;48(Suppl S):S377.
111. Furie R, Lisse J, Merrill JT, Petri M, Ginzler E, Aranow C, et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS]) improves or stabilizes SLE activity in a multicenter phase 2 trial. Arthritis Rheum 2006;54(Suppl S):S790.
112. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT, et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 2006;54(Suppl):S790.
113. Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314-8.
114. Jones DS, Barstad PA, Feild MJ, Hachmann JP, Hayag MS, Hill KW, et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995;38:2138-44.
115. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65.
116. Joshi M, Madaio MP. Role of abetimus in systemic lupus erythematosus. Future Rheumatol 2006;1:167-71.
117. Furie R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am 2006;32:149-56.
118. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
119. Strand V, Aranow C, Cardiel MH, Alarcon-Segovia D, Furie R, Sherrer Y, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86.
120. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004;24:579-90.
121. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral Blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004;137:513-20.
122. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72.